Valeant sales rise on deals; Regeneron's Eylea falls short; Dendreon, Ariad aided by cost cuts

Save

From a slight rise in revenue at the struggling cancer drugmaker Dendreon to a deal-fed increase at Valeant Pharmaceuticals to an against-the-odds upward tick at Germany's Stada, some smaller drugmakers are thumbing their noses at Big Pharma's downward trend this quarter.